ONE-WAYOngoing theme · still written in the latest filings

PPMX-T004 CDH3-targeted ADC development and out-licensing to FUJIFILM

An individual development program for the CDH3-targeted antibody-drug conjugate PPMX-T004, involving continued preliminary toxicity studies after out-licensing to FUJIFILM and evaluation of the efficacy-toxicity balance.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2021 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat